報價延遲最少15分鐘:2025/09/05 18:01 EDT
盤後時段
|
||||
|
13.69 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.43
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-7.58/-1.86
|
|
企業價值
653.17M
|
| 資產負債 |
|
每股賬面淨值
8.47
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.08M
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/05 18:01 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR. |
